NCT07391319招募中3 期
"Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Study of the Efficacy and Safety of the Drug Neovasculgen® Lyophilisate for the Preparation of a Solution for Intramuscular Administration 1.2 mg", Manufacturer Federal State Budgetary Institution "NMITs of Hematology" of the Ministry of Health of the Russian Federation, Russia in Patients With Diabetic Foot Syndrome"
JSC NextGen1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2025年2月11日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Number of participants who achieved complete healing of the ulcer defect through study completion, an average of 6 months
研究概览
简要总结
The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients aged 18 years and above inclusive (at the time of study entry) with neuroischemic form of diabetic foot syndrome.
- •Type 1 or type 2 diabetes mellitus.
- •Prolonged non-healing ulcerative defect on the background of standard therapy (at least 1 month), limited to the foot.
- •Depth of ulcer defect according to Wagner Scale- 1 or 2 degrees.
- •Oxygen tension in the tissues directly adjacent to the ulcer defect area, from 20 to 45 mm Hg.
- •Patients with no urgent indications for limb amputation.
- •Acceptable ankle- brachial index range of 1.3-0.
- •Patient's willingness to comply with the requirements for examination and treatment.
- •Availability of written informed consent from the patient.
- •Patient's consent to follow the regimen of unloading the affected area throughout the study (for patients with plantar ulcer location)
排除标准
- •Chronic ischemia of the lower limbs of non-atherosclerotic (other than diabetes mellitus) origin: vasculitis, systemic connective tissue diseases, Buerger's disease, congenital anomalies and vascular injuries, embolism.
- •Calcaneal localization of the ulcer.
- •Neuropathic form of diabetic foot syndrome.
- •Severe neuroosteoarthropathic deformity of the foot or other deformity that has a significant impact on the healing process.
- •Ischemia, threatening limb loss.
- •Presence of clinical signs of an infectious process in the ulcer area that is not controlled by the ongoing antibacterial therapy.
- •Presence of purulent-destructive lesions of the foot (abscess, phlegmon, osteomyelitis, etc.).
- •Skin changes associated with venous pathology.
- •Proliferative and terminal stages of diabetic retinopathy.
- •The level of glycated hemoglobin at the entrance to the study is more than 11%.
- •Diabetic ketoacidosis or diabetic precoma.
- •Systemic use of glucocorticosteroids and/or other immunosuppressive drugs within the last 30 days before inclusion in the study.
- •Recent (less than 1 month) surgery or endovascular intervention on the arteries of the lower extremities or recent (less than 1 month) deep vein thrombosis of the lower extremities.
- •Recent (less than 3 months) cases of acute myocardial infarction, unstable angina, coronary artery bypass grafting or stenting of the coronary arteries, stroke or transient ischemic attacks.
- •Planned major surgery in the next 6 months.
- •Severe concomitant disease with life expectancy less than one year.
- •Infectious diseases, septic conditions, HIV infection.
- •Diagnosis of cancer within the last 5 years.
- •Pregnancy, breastfeeding period.
- •Positive pregnancy test in women of reproductive age.
- •Alcohol or drug addiction.
- •Any other disease (including mental) or clinical condition that, in the opinion of the researcher, may affect the patient's ability to participate in the study.
研究组 & 干预措施
The investigational therapy group (Neovasculgen)
Experimental
The diluted drug will be administered by 5-10 injections intramuscularly twice with an interval of 14 days, in the course dosage mode - 2.4 mg.
干预措施: Neovasculgen® (Drug)
The placebo group
Placebo Comparator
Placebo will be administered by 5-10 injections intramuscularly twice with an interval of 14 days
干预措施: Placebo (Drug)
结局指标
主要结局
Number of participants who achieved complete healing of the ulcer defect through study completion, an average of 6 months
时间窗: Until the end of the study
次要结局
- Number of participants with partial ulcer defect healing through study completion, an average of 6 months(Until the end of the study)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
招募中
2 期
Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)2024-514386-19-00Universitaetsklinikum Essen AöR58
招募中
3 期
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423Novo Nordisk A/S1,150
尚未招募
1 期
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric CancerNCT07333573Shanghai Zhongshan Hospital42
招募中
2 期
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692RenJi Hospital46